Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe

David Moreno-Martos; Katia Verhamme; Anna Ostropolets; Kristin Kostka; Talita Duarte-Sales; Daniel Prieto-Alhambra; Thamir M Alshammari; Heba Alghoul; Waheed-Ul-Rahman Ahmed; Clair Blacketer; Scott DuVall; Lana Lai; Michael Matheny; Fredrik Nyberg; Jose Posada; Peter Rijnbeek; Matthew Spotnitz; Anthony Sena; Nigam Shah; Marc Suchard; Seng Chan You; George Hripcsak; Patrick Ryan; Daniel Morales

doi:10.12688/wellcomeopenres.17403.2

Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe

David Moreno-Martos, Katia Verhamme, Anna Ostropolets, Kristin Kostka, Talita Duarte-Sales, Daniel Prieto-Alhambra, Thamir M Alshammari, Heba Alghoul, Waheed-Ul-Rahman Ahmed, Clair Blacketer, Scott DuVall, Lana Lai, Michael Matheny, Fredrik Nyberg, Jose Posada, Peter Rijnbeek, Matthew Spotnitz, Anthony Sena, Nigam Shah, Marc SuchardSeng Chan You, George Hripcsak, Patrick Ryan, Daniel Morales^*

^*Corresponding author for this work

Medical Informatics

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

18 Downloads (Pure)

Abstract

Background: Characterization studies of COVID-19 patients with chronic obstructive pulmonary disease (COPD) are limited in size and scope. The aim of the study is to provide a large-scale characterization of COVID-19 patients with COPD. Methods: We included thirteen databases contributing data from January-June 2020 from North America (US), Europe and Asia. We defined two cohorts of patients with COVID-19 namely a 'diagnosed' and 'hospitalized' cohort. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes among COPD patients with COVID-19. Results: The study included 934,778 patients in the diagnosed COVID-19 cohort and 177,201 in the hospitalized COVID-19 cohort. Observed COPD prevalence in the diagnosed cohort ranged from 3.8% (95%CI 3.5-4.1%) in French data to 22.7% (95%CI 22.4-23.0) in US data, and from 1.9% (95%CI 1.6-2.2) in South Korean to 44.0% (95%CI 43.1-45.0) in US data, in the hospitalized cohorts. COPD patients in the hospitalized cohort had greater comorbidity than those in the diagnosed cohort, including hypertension, heart disease, diabetes and obesity. Mortality was higher in COPD patients in the hospitalized cohort and ranged from 7.6% (95%CI 6.9-8.4) to 32.2% (95%CI 28.0-36.7) across databases. ARDS, acute renal failure, cardiac arrhythmia and sepsis were the most common outcomes among hospitalized COPD patients. Conclusion: COPD patients with COVID-19 have high levels of COVID-19-associated comorbidities and poor COVID-19 outcomes. Further research is required to identify patients with COPD at high risk of worse outcomes.

Original language	English
Article number	22
Number of pages	25
Journal	Wellcome Open Research
Volume	7
DOIs	https://doi.org/10.12688/wellcomeopenres.17403.2
Publication status	Published - 10 Jan 2023

Bibliographical note

Grant information: The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint
Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and
innovation programme and EFPIA; This research received partial support from the National Institute for Health Research (NIHR) Oxford
Biomedical Research Centre (BRC), US National Institutes of Health, US Department of Veterans Affairs, Janssen Research &
Development, and IQVIA; The University of Oxford received funding related to this work from the Bill & Melinda Gates Foundation
(Investment ID INV-016201 and INV-019257); IDIAPJGol received funding from the Health Department from the Generalitat de Catalunya
with a grant for research projects on SARS-CoV-2 and COVID-19 disease organized by the Direcció General de Recerca i Innovació en
Salut; DPA receives funding from NIHR Academy in the form of an NIHR Senior Research Fellowship. The views and opinions expressed
are those of the authors and do not necessarily reflect those of the Clinician Scientist Award programme, NIHR, United States
Department of Veterans Affairs or the United States Government, NHS, or the Department of Health, England; DRM is supported by a
Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z, https://doi.org/10.35802/214588); and DMM is funded
by Health Data Research-UK.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2022 Moreno-Martos D et al.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.12688/wellcomeopenres.17403.2Licence: CC BY

David_moreno_martos_v3Final published version, 1.93 MBLicence: CC BY

Cite this

Moreno-Martos, D., Verhamme, K., Ostropolets, A., Kostka, K., Duarte-Sales, T., Prieto-Alhambra, D., Alshammari, T. M., Alghoul, H., Ahmed, W.-U.-R., Blacketer, C., DuVall, S., Lai, L., Matheny, M., Nyberg, F., Posada, J., Rijnbeek, P., Spotnitz, M., Sena, A., Shah, N., ... Morales, D. (2023). Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe. Wellcome Open Research, 7, Article 22. https://doi.org/10.12688/wellcomeopenres.17403.2

@article{c50fd30b4ff74c8b8fa4434c5ee16e18,

title = "Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe",

abstract = "Background: Characterization studies of COVID-19 patients with chronic obstructive pulmonary disease (COPD) are limited in size and scope. The aim of the study is to provide a large-scale characterization of COVID-19 patients with COPD. Methods: We included thirteen databases contributing data from January-June 2020 from North America (US), Europe and Asia. We defined two cohorts of patients with COVID-19 namely a 'diagnosed' and 'hospitalized' cohort. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes among COPD patients with COVID-19. Results: The study included 934,778 patients in the diagnosed COVID-19 cohort and 177,201 in the hospitalized COVID-19 cohort. Observed COPD prevalence in the diagnosed cohort ranged from 3.8% (95%CI 3.5-4.1%) in French data to 22.7% (95%CI 22.4-23.0) in US data, and from 1.9% (95%CI 1.6-2.2) in South Korean to 44.0% (95%CI 43.1-45.0) in US data, in the hospitalized cohorts. COPD patients in the hospitalized cohort had greater comorbidity than those in the diagnosed cohort, including hypertension, heart disease, diabetes and obesity. Mortality was higher in COPD patients in the hospitalized cohort and ranged from 7.6% (95%CI 6.9-8.4) to 32.2% (95%CI 28.0-36.7) across databases. ARDS, acute renal failure, cardiac arrhythmia and sepsis were the most common outcomes among hospitalized COPD patients. Conclusion: COPD patients with COVID-19 have high levels of COVID-19-associated comorbidities and poor COVID-19 outcomes. Further research is required to identify patients with COPD at high risk of worse outcomes.",

author = "David Moreno-Martos and Katia Verhamme and Anna Ostropolets and Kristin Kostka and Talita Duarte-Sales and Daniel Prieto-Alhambra and Alshammari, {Thamir M} and Heba Alghoul and Waheed-Ul-Rahman Ahmed and Clair Blacketer and Scott DuVall and Lana Lai and Michael Matheny and Fredrik Nyberg and Jose Posada and Peter Rijnbeek and Matthew Spotnitz and Anthony Sena and Nigam Shah and Marc Suchard and {Chan You}, Seng and George Hripcsak and Patrick Ryan and Daniel Morales",

note = "Grant information: The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation programme and EFPIA; This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), US National Institutes of Health, US Department of Veterans Affairs, Janssen Research & Development, and IQVIA; The University of Oxford received funding related to this work from the Bill & Melinda Gates Foundation (Investment ID INV-016201 and INV-019257); IDIAPJGol received funding from the Health Department from the Generalitat de Catalunya with a grant for research projects on SARS-CoV-2 and COVID-19 disease organized by the Direcci{\'o} General de Recerca i Innovaci{\'o} en Salut; DPA receives funding from NIHR Academy in the form of an NIHR Senior Research Fellowship. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award programme, NIHR, United States Department of Veterans Affairs or the United States Government, NHS, or the Department of Health, England; DRM is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z, https://doi.org/10.35802/214588); and DMM is funded by Health Data Research-UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Copyright: {\textcopyright} 2022 Moreno-Martos D et al.",

year = "2023",

month = jan,

day = "10",

doi = "10.12688/wellcomeopenres.17403.2",

language = "English",

volume = "7",

journal = "Wellcome Open Research",

issn = "2398-502X",

publisher = "F1000 Research Ltd",

}

Moreno-Martos, D, Verhamme, K, Ostropolets, A, Kostka, K, Duarte-Sales, T, Prieto-Alhambra, D, Alshammari, TM, Alghoul, H, Ahmed, W-U-R, Blacketer, C, DuVall, S, Lai, L, Matheny, M, Nyberg, F, Posada, J, Rijnbeek, P, Spotnitz, M, Sena, A, Shah, N, Suchard, M, Chan You, S, Hripcsak, G, Ryan, P & Morales, D 2023, 'Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe', Wellcome Open Research, vol. 7, 22. https://doi.org/10.12688/wellcomeopenres.17403.2

TY - JOUR

T1 - Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe

AU - Moreno-Martos, David

AU - Verhamme, Katia

AU - Ostropolets, Anna

AU - Kostka, Kristin

AU - Duarte-Sales, Talita

AU - Prieto-Alhambra, Daniel

AU - Alshammari, Thamir M

AU - Alghoul, Heba

AU - Ahmed, Waheed-Ul-Rahman

AU - Blacketer, Clair

AU - DuVall, Scott

AU - Lai, Lana

AU - Matheny, Michael

AU - Nyberg, Fredrik

AU - Posada, Jose

AU - Rijnbeek, Peter

AU - Spotnitz, Matthew

AU - Sena, Anthony

AU - Shah, Nigam

AU - Suchard, Marc

AU - Chan You, Seng

AU - Hripcsak, George

AU - Ryan, Patrick

AU - Morales, Daniel

N1 - Grant information: The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA; This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), US National Institutes of Health, US Department of Veterans Affairs, Janssen Research & Development, and IQVIA; The University of Oxford received funding related to this work from the Bill & Melinda Gates Foundation (Investment ID INV-016201 and INV-019257); IDIAPJGol received funding from the Health Department from the Generalitat de Catalunya with a grant for research projects on SARS-CoV-2 and COVID-19 disease organized by the Direcció General de Recerca i Innovació en Salut; DPA receives funding from NIHR Academy in the form of an NIHR Senior Research Fellowship. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award programme, NIHR, United States Department of Veterans Affairs or the United States Government, NHS, or the Department of Health, England; DRM is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z, https://doi.org/10.35802/214588); and DMM is funded by Health Data Research-UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Copyright: © 2022 Moreno-Martos D et al.

PY - 2023/1/10

Y1 - 2023/1/10

N2 - Background: Characterization studies of COVID-19 patients with chronic obstructive pulmonary disease (COPD) are limited in size and scope. The aim of the study is to provide a large-scale characterization of COVID-19 patients with COPD. Methods: We included thirteen databases contributing data from January-June 2020 from North America (US), Europe and Asia. We defined two cohorts of patients with COVID-19 namely a 'diagnosed' and 'hospitalized' cohort. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes among COPD patients with COVID-19. Results: The study included 934,778 patients in the diagnosed COVID-19 cohort and 177,201 in the hospitalized COVID-19 cohort. Observed COPD prevalence in the diagnosed cohort ranged from 3.8% (95%CI 3.5-4.1%) in French data to 22.7% (95%CI 22.4-23.0) in US data, and from 1.9% (95%CI 1.6-2.2) in South Korean to 44.0% (95%CI 43.1-45.0) in US data, in the hospitalized cohorts. COPD patients in the hospitalized cohort had greater comorbidity than those in the diagnosed cohort, including hypertension, heart disease, diabetes and obesity. Mortality was higher in COPD patients in the hospitalized cohort and ranged from 7.6% (95%CI 6.9-8.4) to 32.2% (95%CI 28.0-36.7) across databases. ARDS, acute renal failure, cardiac arrhythmia and sepsis were the most common outcomes among hospitalized COPD patients. Conclusion: COPD patients with COVID-19 have high levels of COVID-19-associated comorbidities and poor COVID-19 outcomes. Further research is required to identify patients with COPD at high risk of worse outcomes.

AB - Background: Characterization studies of COVID-19 patients with chronic obstructive pulmonary disease (COPD) are limited in size and scope. The aim of the study is to provide a large-scale characterization of COVID-19 patients with COPD. Methods: We included thirteen databases contributing data from January-June 2020 from North America (US), Europe and Asia. We defined two cohorts of patients with COVID-19 namely a 'diagnosed' and 'hospitalized' cohort. We followed patients from COVID-19 index date to 30 days or death. We performed descriptive analysis and reported the frequency of characteristics and outcomes among COPD patients with COVID-19. Results: The study included 934,778 patients in the diagnosed COVID-19 cohort and 177,201 in the hospitalized COVID-19 cohort. Observed COPD prevalence in the diagnosed cohort ranged from 3.8% (95%CI 3.5-4.1%) in French data to 22.7% (95%CI 22.4-23.0) in US data, and from 1.9% (95%CI 1.6-2.2) in South Korean to 44.0% (95%CI 43.1-45.0) in US data, in the hospitalized cohorts. COPD patients in the hospitalized cohort had greater comorbidity than those in the diagnosed cohort, including hypertension, heart disease, diabetes and obesity. Mortality was higher in COPD patients in the hospitalized cohort and ranged from 7.6% (95%CI 6.9-8.4) to 32.2% (95%CI 28.0-36.7) across databases. ARDS, acute renal failure, cardiac arrhythmia and sepsis were the most common outcomes among hospitalized COPD patients. Conclusion: COPD patients with COVID-19 have high levels of COVID-19-associated comorbidities and poor COVID-19 outcomes. Further research is required to identify patients with COPD at high risk of worse outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85152937531&partnerID=8YFLogxK

U2 - 10.12688/wellcomeopenres.17403.2

DO - 10.12688/wellcomeopenres.17403.2

M3 - Article

C2 - 36845321

SN - 2398-502X

VL - 7

JO - Wellcome Open Research

JF - Wellcome Open Research

M1 - 22

ER -

Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this